Publications

5674 Results

S2408: A randomized phase III blinded trial of lanreotide for the prevention of postoperative pancreatic fistula

Authors
J Sham;V Pillarisetty;K Guthrie;K Arnold;R Topacio;K Carvalho;G Wright;V Sun;F Rocha;S Ahmad;R Krouse
Journal / Conference
ASCO GI Cancers Symposium (January 8 - 10, 2026, San Francisco, CA)
Year
2025
Research Committee(s)
Palliative Care
Study Number(s)
S2408

Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer

Authors
L Pusztai;J Hoag;K Albain;W Barlow;S Stemmer;A Meisner;G Hortobagyi;S Shak;J Rae;R Baehner;P Sharma;K Kalinsky
Journal / Conference
Journal of Clinical Oncology
Year
2025
Research Committee(s)
Breast
PMID
PMID39621968
PMC
PMC11885031
Study Number(s)
S1007, SWOG-8814

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study

Authors
P Mack;M Redman;H Tukachinsky;D Kozono;S Callis;K Tolba;J Neal;S Waqar;K Dragnev;C Aggarwal;F Hirsch;J Patel;R Herbst;A Chiang;K Reckamp;K Kelly;H Borghaei;J Gray;D Gandara
Journal / Conference
Clinical Cancer Research Aug 14;31(16):3550-3561
Year
2025
Research Committee(s)
Lung
PMID
PMID40465842
Study Number(s)
LUNGMAP

Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive induction chemotherapy: Secondary analysis of SWOG S1203

Authors
S Raychaudhuri;M Othus;M Percival;G Garcia-Manero;F Appelbaum;H Erba;J Appelbaum
Journal / Conference
Blood Neoplasia Jun 14;2(3):100129
Year
2025
Research Committee(s)
Leukemia
PMID
PMID40792015
PMC
PMC12335950
Study Number(s)
S1203

GABAergic signaling contributes to tumor cell invasion and poor overall survival in colorectal cancer

Journal / Conference
Oncogene Aug 24. doi: 10.1038/s41388-025-03546-2. Online ahead of print
Year
2025

Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)

Authors
F Battaglin;B O'Neil;S Stintzing;F Ou;T Zemla;D Niedzwiecki;F Innocenti;H Hochster;L von Weikersthal;T Decker;A Kiani;U Vehling-Kaiser;T Heintges;C Lerchenmuller;L Weiss;K Heinrich;R Goldberg;R Mayer;R Schilsky;C Blanke;A Venook;H-J Lenz;V Heinemann
Journal / Conference
European Journal of Cancer Sep 9:227:115694
Year
2025
Research Committee(s)
Gastrointestinal
PMID
PMID40803104
Study Number(s)
CTSU/C80405

Biobanking and consent to future biospecimen use among adults enrolled in SWOG trials from 2000 to 2024

Authors
D Olivieri;A Berridge-Green;M Othus;J Radich;A Advani;H Erba;R Walter
Journal / Conference
Blood Cancer Journal May 3;15(1):85
Year
2025
PMID
PMID40319052
PMC
PMC12049410

First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors

Authors
M Othus;S Patel;Y Chae;E Dietrich;H Streicher;E Sharon;R Kurzrock
Journal / Conference
Journal of the National Cancer Institute Apr 1;117(4):692-700
Year
2025
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID39565908
PMC
PMC11972677
Study Number(s)
S1609

TRIPLE-SWITCH(SWOG/CCTG-PR26): Randomized Phase III Clinical Trial of Docetaxel with Androgen Receptor Pathway Inhibitors for Metastatic Castration-Sensitive Prostate Cancer Patients with a Suboptimal PSA Response

Authors
M Ong;A Sokolova;S Hotte;T Dorff;K Chi;A Wyatt;A Goldkorn;M Kolinsky;M Brundage;A Ndika;S Lerner;W Parulekar;K Ding;M Jafri
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), tip; Abstract # TPS5129 Poster Bd # 318b
Year
2025
Research Committee(s)
Genitourinary

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

Authors
T Parker;A Rosenthal;V Sanchorawala;H Landau;E Campagnaro;P Kapoor;N Neparidze;S Girnius;P Hagen;E Scott;A Hoering;B Durie;R Orlowski
Journal / Conference
Blood Sep 9:blood.2024027962
Year
2025
Research Committee(s)
Myeloma
PMID
PMID40925099
Study Number(s)
S1702